Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend
International Journal of Molecular Medicine · 2026
DOI: 10.3892/ijmm.2026.5773 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2026. Verfasst von Peng-Yao Lin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, P.R. China. Hauptthemen laut MEDLINE: PPAR alpha, Non-alcoholic Fatty Liver Disease, Thiazines, Liver. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Food additive acesulfame‑K (AK), a non‑nutritive sweetener, is widely used as a low‑calorie sugar substitute to reduce energy intake. However, its potential impact on nonalcoholic fatty liver disease (NAFLD) and the involvement of peroxisome proliferator‑activated receptor α (PPARα) remain unclear. In the present study, male wild‑type (WT) and PPARα‑null (KO) mice fed a 60% high‑fat diet were treated with AK (2 mg/ml) in drinking water for 12 weeks to evaluate the effects of chronic AK exposure on NAFLD progression and the role of PPARα. PPARα inhibition and activation strategies were further applied in in vivo and in vitro models to validate the key findings. AK supplementation markedly increased hepatic lipid accumulation and impaired glucose tolerance through activation of phospholipase C beta (PLCβ) in hepatic sweet taste receptor (STR) signaling in the WT mice, but not in the KO mice. Consistently, PLCβ activation was observed in AK‑induced lipid accumulation in Hepa1‑6 and Huh‑7 cells and was abolished by PPARα knockdown or inhibition. Pharmacological activation of PPARα mitigated AK‑induced NAFLD progression by suppressing PLCβ activation in STR signaling. These findings demonstrated that chronic AK intake exacerbates NAFLD progression via PLCβ activation in hepatic STR signaling and that PLCβ activation depends on physiological PPARα activity. Pharmacological PPARα activation exerts a protective effect, highlighting the dual roles of PPARα in regulating AK‑associated NAFLD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, P.R. China.
- Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310027, P.R. China.
- Department of Pharmacology, Health Science Center, Ningbo University, Ningbo, Zhejiang 315211, P.R. China.
- Ningbo Clinical Pathology Diagnosis Center, Ningbo, Zhejiang 315021, P.R. China.
Zitieren
APA
Lin, P. Y., Xie, J. R., Qian, T. C., Wang, S. S., Yu, S. Y., Shi, W. B., Wang, Y., Cen, L. Z., Zhu, Q. J., Zheng, Y. Y., Gao, H., Fang, R., Xia, Z. X., Liu, A. M., & Xu, L. (2026). Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2026.5773
Vancouver
Lin PY, Xie JR, Qian TC, Wang SS, Yu SY, Shi WB, et al. Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend. International Journal of Molecular Medicine. 2026. doi:10.3892/ijmm.2026.5773
BibTeX
@article{Lin2026,
author = {Lin, Peng-Yao and Xie, Jia-Rong and Qian, Tian-Chen and Wang, Shi-Song and Yu, Si-Yi and Shi, Wen-Bo and Wang, Ying and Cen, Lu-Ze and Zhu, Qing-Jing and Zheng, Yi-Yang and Gao, Hui and Fang, Rong and Xia, Zhao-Xia and Liu, Ai-Ming and Xu, Lei},
title = {Peroxisome proliferator‑activated receptor α regulates acesulfame‑K‑induced NAFLD via hepatic PLCβ: Foe and friend},
journal = {International Journal of Molecular Medicine},
year = {2026},
doi = {10.3892/ijmm.2026.5773}
}
EUVIMED